The United States Food and Drug Administration (USFDA) has issued a warning letter to the manufacturing facility of Vista Pharmaceuticals Ltd. in Nalgonda for “significant violations of current good manufacturing practice regulations for finished pharmaceuticals.”The warning letter, issued earlier this month, follows the USFDA inspection of the facility at the APIIC Industrial Estate in Gopalapalli, Narketpalli in September last year.